Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Cancer. 2023 Apr 15;129(8):1217-1226. doi: 10.1002/cncr.34665. Epub 2023 Feb 3.
The gold standard for the identification of Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) patients is gene expression profiling. Because of its diverse nature, its identification is extremely difficult and expensive. On the genomic and proteomic landscape of Ph-like ALL patients, there is a paucity of published literature from developing countries.
The authors used digital barcoded nCounter NanoString gene expression profiling for its detection, followed by molecular and proteomic characterization using fluorescence in situ hybridization and liquid chromatography-tandem mass spectrometry (LC-MS/MS).
The authors found 32.05% Ph-like ALL patients and their median age at presentation was considerably higher than Ph-negative ALL cases (p = .0306). Furthermore, we identified 20% CRLF2 overexpressed cases having 8.33% CRLF2-IGH translocation with concomitant R683S mutation and 8.33% CRLF2-P2RY8 translocation. In 80% of CRLF2 downregulated cases, we identified 10% as having JAK2 rearrangement. Minimal residual disease-positivity was more common in Ph-like ALL cases (55.55% vs. 25% in Ph-negative ALL cases). Immunoglobulin J chain (Jchain), small nuclear ribonucleoprotein SmD1 (SNRPD1), immunoglobulin κ constant (IGKC), NADH dehydrogenase (ubiquinone) 1 α subcomplex subunit 2 (NDUFA2), histone H2AX (H2AFX), charged multivesicular body protein 4b (CHMP4B), and carbonyl reductase (NADPH) (CBR1) proteins were identified to be substantially expressed in Ph-like ALL patients, using LC-MS/MS. Gene enrichment analysis indicated that involvement of spliceosomal mediated messenger RNA splicing pathway and four microRNAs was statistically significant in Ph-like ALL patients.
For the first time, we have described incidence, molecular, and proteomic characterization of Ph-like ALL, in developing nations.
In developing countries, detecting Philadelphia (Ph)-like B-lineage acute lymphoblastic leukemia is complicated and challenging due to its diverse genetic landscape. There is no well-defined and cost-effective methodology for its detection. The incidence of this high-risk subtype is very high in adult cases, and there is an urgent need for its accurate detection. We have developed an online PHi-RACE classifier for its rapid detection, followed by delineating the genomic and proteomic landscape of Ph-like acute lymphoblastic leukemias for the first time in Indian patients.
鉴定费城(Ph)样急性淋巴细胞白血病(ALL)患者的金标准是基因表达谱分析。由于其多样性,鉴定非常困难且昂贵。在 Ph 样 ALL 患者的基因组和蛋白质组景观中,来自发展中国家的文献很少。
作者使用数字条形码 nCounter NanoString 基因表达谱分析进行检测,然后使用荧光原位杂交和液相色谱-串联质谱(LC-MS/MS)进行分子和蛋白质组学特征分析。
作者发现 32.05%的 Ph 样 ALL 患者,其发病时的中位年龄明显高于 Ph 阴性 ALL 病例(p = 0.0306)。此外,我们还发现 20%的 CRLF2 过表达病例存在 8.33%的 CRLF2-IGH 易位,伴有 R683S 突变和 8.33%的 CRLF2-P2RY8 易位。在 80%的 CRLF2 下调病例中,我们发现 10%的病例存在 JAK2 重排。Ph 样 ALL 病例的微小残留病阳性更为常见(55.55% vs. Ph 阴性 ALL 病例的 25%)。使用 LC-MS/MS,鉴定到 Ph 样 ALL 患者中免疫球蛋白 J 链(Jchain)、小核仁核糖核蛋白 SmD1(SNRPD1)、免疫球蛋白 κ 恒定(IGKC)、NADH 脱氢酶(泛醌)1α 亚基 2(NDUFA2)、组蛋白 H2AX(H2AFX)、带电荷多泡体蛋白 4b(CHMP4B)和羰基还原酶(NADPH)(CBR1)蛋白的表达水平显著升高。基因富集分析表明,拼接体介导的信使 RNA 剪接途径和四个 microRNA 的参与在 Ph 样 ALL 患者中具有统计学意义。
这是首次在发展中国家描述 Ph 样 ALL 的发病情况、分子和蛋白质组学特征。